NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

Core Viewpoint - Aquestive Therapeutics, Inc. is under investigation for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm, impacting its market commitments and labeling discussions [1]. Company Summary - On January 9, 2026, Aquestive announced it received a letter from the FDA regarding deficiencies in its NDA application for Anaphylm, which is intended for the emergency treatment of anaphylaxis [1]. - Following this announcement, Aquestive's stock price dropped by $2.18, representing a 35.1% decline, opening at $4.03 [2]. Legal Context - Levi & Korsinsky LLP has initiated an investigation into Aquestive Therapeutics, focusing on potential recovery options for investors who may have suffered losses due to the recent developments [2]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [3].

Core Viewpoint - The stock price of Aquestive Therapeutics (AQST) has recently experienced a significant decline of 45.2% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out of the stock, with selling pressure likely subsiding, which could lead to a bullish trend [2][5]. - A hammer pattern is characterized by a small candle body with a long lower wick, indicating that despite a downtrend, buying interest has emerged to push the stock price up towards the opening price [4][5]. - The effectiveness of the hammer pattern as a bullish indicator is enhanced when used alongside other bullish indicators [6]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for AQST, which is a bullish sign indicating potential price appreciation in the near term [7]. - The consensus EPS estimate for AQST has increased by 1.3% over the last 30 days, reflecting analysts' agreement on the company's improved earnings potential [8]. - AQST holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically indicates strong market performance [9][10].

Core Viewpoint - Aquestive Therapeutics, Inc. is under investigation for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm, leading to a significant drop in stock price [1][2]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious medical conditions, including anaphylaxis [1]. - The company’s stock price fell by $2.18 (35.1%) to open at $4.03 in response to the FDA's findings [2]. Group 2: Regulatory Impact - The FDA's letter indicates that the deficiencies in the NDA application preclude any discussions regarding labeling and post-market commitments for Anaphylm [1]. - This regulatory setback could have significant implications for the company's market position and future revenue potential [1]. Group 3: Legal Implications - Levi & Korsinsky has initiated an investigation into the company, indicating potential legal ramifications for shareholders who may have suffered losses [2]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [3].

Core Viewpoint - Block & Leviton is investigating Aquestive Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price due to FDA deficiencies in its drug application [1][2]. Group 1: Company Overview - Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that the FDA identified deficiencies in its new drug application for Anaphylm, raising the risk of delayed approval [2]. - Block & Leviton is investigating the company's prior disclosures to determine if there were any violations of securities laws [4]. Group 2: Investor Eligibility - Any investor who purchased common stock of Aquestive Therapeutics and has experienced a decline in their investment may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Group 3: Legal Actions and Support - Block & Leviton is prepared to file an action to recover losses on behalf of investors who have lost money due to the company's disclosures [4]. - Investors who have non-public information about Aquestive Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many top institutional investors [7].

Core Insights - The article discusses the investment analysis of Aquestive Therapeutics (AQST), highlighting a cautious BUY rating based on the information available at the time [1]. Company Analysis - The focus is on identifying potential high-growth opportunities, specifically targeting small- and mid-cap companies in the life sciences sector, which includes early-commercial-stage firms [1]. - The analysis emphasizes careful fundamental evaluation of businesses, financials, and valuations to uncover potential 5–10 baggers [1]. Analyst Background - The author operates a boutique law firm specializing in investment transactions and disputes, with training from top U.S. law schools and leading Wall Street law firms [1]. - The intent behind writing is to refine analytical thinking and engage with followers, ensuring that the content is accessible to a broad audience [1].

Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% following the FDA's identification of deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the upcoming PDUFA action date [5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions [5]. - The company is publicly traded on NASDAQ under the ticker symbol AQST [2]. Group 2: Recent Developments - The FDA has identified deficiencies in the New Drug Application for Anaphylm, which is an experimental sublingual film intended for the treatment of severe allergic reactions, including anaphylaxis [5]. - The deficiencies noted by the FDA currently prevent discussions regarding labeling and post-marketing requirements, which raises concerns about the likelihood of the application being approved by the January 31, 2026 PDUFA action date [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [2][4].

Core Viewpoint - Aquestive Therapeutics (AQST) has experienced a significant decline of 37% over the past four weeks, but it is now in oversold territory, suggesting a potential for a turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - AQST's current RSI reading is 20.13, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Analysis - Analysts covering AQST have shown strong agreement in raising earnings estimates, with the consensus EPS estimate increasing by 0.4% over the last 30 days, which typically correlates with price appreciation [7]. - AQST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Market Overview - Stock futures are modestly higher following the December nonfarm payrolls report and ahead of a Supreme Court decision on President Trump's tariff policy [1] - Major indexes have shown resilience early in 2026 after a strong finish to 2025, but gains have faced headwinds due to cooling tech momentum and uncertainty around labor data affecting Federal Reserve policy expectations [1] Sector Performance - Defensive sectors such as energy and mining have demonstrated relative strength, while value-oriented and cyclical areas are gaining attention amid market rotation [2] - Safe-haven assets like gold have seen increased demand as risk sentiment fluctuates [2] Pre-Market Trading - In pre-market trading, S&P 500 futures rose by 0.33%, Nasdaq futures increased by 0.42%, and Dow futures were up by 0.32% [2] Company Movements - Oklo (OKLO) is up 18% after announcing an agreement with Meta Platforms (META) to develop a 1.2 GW power campus in Pike County, Ohio [5] - Vistra (VST) increased by 17% after entering into 20-year purchase power agreements to provide over 2,600 megawatts of zero-carbon energy from three nuclear plants for Meta's operations [5] - Intel (INTC) rose by 2% following President Trump's positive remarks about a meeting with CEO Lip-Bu Tan [5] - Offerpad Solutions (OPAD) surged by 48%, LoanDepot (LDI) increased by 16%, Opendoor Technologies (OPEN) rose by 11%, Rocket Companies (RKT) was up by 6%, and UWM Holdings (UWMC) also increased by 6% [5] - Conversely, Aquestive Therapeutics (AQST) fell by 37% after the FDA identified deficiencies in its Anaphylm NDA, while AXT Inc. (AXTI) dropped by 14% after cutting its Q4 revenue outlook [5]

Market Overview - U.S. equities ended the first full trading week of 2026 positively, with major benchmarks like the S&P 500 and Dow Jones Industrial Average reaching new record highs, influenced by geopolitical events and a mixed December jobs report [2] - Investors shifted focus from mega-cap technology stocks to cyclical sectors, particularly energy and defense, following a significant U.S. military operation in Venezuela and expectations of increased crude supply [2][3] Sector Performance - Energy and defense stocks led the market gains, with oil-related equities rising due to optimism about Venezuela's potential to supply crude oil to U.S. markets, while defense contractors benefited from plans for a larger Pentagon budget in 2027 [3] - Smaller defense contractors outperformed the broader market, indicating a shift in market leadership influenced by geopolitical factors [3] Economic Data - The December jobs report indicated slower than expected payroll growth but a lower unemployment rate, alleviating some investor concerns regarding labor market stress [4] - Mixed sentiments around inflation and labor conditions suggested that the Federal Reserve may maintain steady interest rates in the near term [4] Notable Stock Movements - Chevron Corp. (NYSE:CVX) shares rose approximately 5.8% following U.S. military actions in Venezuela, which boosted investor optimism about accessing Venezuelan oil resources [5] - Palantir Technologies Inc. (NASDAQ:PLTR) stock gained momentum amid speculation of its involvement in U.S. military operations in Venezuela, attracting attention from investors and analysts [6] - Nuclear energy stocks, including Centrus Energy Corp. (NYSE:LEU) and Energy Fuels Inc. (NYSE:UUUU), rallied after the Trump administration announced expanded federal support for domestic nuclear infrastructure, enhancing long-term demand prospects [7] Bearish Trends - Real estate and housing-linked stocks experienced significant sell-offs after President Trump announced plans to limit large institutional investors from purchasing single-family homes, impacting major players like Blackstone Inc. (NYSE:BX) and Invitation Homes Inc. (NASDAQ:INVH) [9] - U.S. defense stocks fell sharply after Trump ordered major defense contractors to halt dividends and share buybacks until they increased investments in production, affecting companies like Lockheed Martin Corp. (NYSE:LMT) and Northrop Grumman Corp. (NYSE:NOC) [10] - Aquestive Therapeutics Inc. (NASDAQ:AQST) shares dropped after the FDA flagged issues with its allergy drug application, raising concerns about potential delays in the approval process [11]